EE200200277A - 4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor - Google Patents
4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitorInfo
- Publication number
- EE200200277A EE200200277A EEP200200277A EEP200200277A EE200200277A EE 200200277 A EE200200277 A EE 200200277A EE P200200277 A EEP200200277 A EE P200200277A EE P200200277 A EEP200200277 A EE P200200277A EE 200200277 A EE200200277 A EE 200200277A
- Authority
- EE
- Estonia
- Prior art keywords
- carboxyamino
- tetrahydroquinoline
- ethyl
- crystal
- cetp inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16805199P | 1999-11-30 | 1999-11-30 | |
| PCT/IB2000/001650 WO2001040190A1 (fr) | 1999-11-30 | 2000-11-14 | Cristaux de 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoleine utilises en tant qu'inhibiteurs de cetp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200200277A true EE200200277A (et) | 2003-10-15 |
Family
ID=22609901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200277A EE200200277A (et) | 1999-11-30 | 2000-11-14 | 4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1246804A1 (fr) |
| JP (1) | JP2003515592A (fr) |
| KR (1) | KR20020058057A (fr) |
| CN (1) | CN1402711A (fr) |
| AP (1) | AP2002002531A0 (fr) |
| AU (1) | AU1048801A (fr) |
| BG (1) | BG106854A (fr) |
| BR (1) | BR0015836A (fr) |
| CA (1) | CA2392979A1 (fr) |
| CO (1) | CO5271716A1 (fr) |
| EA (1) | EA200200510A1 (fr) |
| EC (1) | ECSP003792A (fr) |
| EE (1) | EE200200277A (fr) |
| GT (1) | GT200000199A (fr) |
| HU (1) | HUP0203521A2 (fr) |
| IL (1) | IL149097A0 (fr) |
| IS (1) | IS6338A (fr) |
| MA (1) | MA26845A1 (fr) |
| MX (1) | MXPA02005354A (fr) |
| NO (1) | NO20022558L (fr) |
| OA (1) | OA12099A (fr) |
| PA (1) | PA8506301A1 (fr) |
| PE (1) | PE20010904A1 (fr) |
| PL (1) | PL355892A1 (fr) |
| TN (1) | TNSN00231A1 (fr) |
| TR (1) | TR200201446T2 (fr) |
| UY (1) | UY26454A1 (fr) |
| WO (1) | WO2001040190A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| BR0210505A (pt) | 2001-06-21 | 2004-05-18 | Pfizer Prod Inc | Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo |
| GT200200170A (es) | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
| EP1920766B1 (fr) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles |
| BR0307344A (pt) | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
| PT1469833T (pt) * | 2002-02-01 | 2021-07-13 | Bend Res Inc | Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado |
| DE60311821T2 (de) | 2002-08-30 | 2007-10-31 | Japan Tobacco Inc. | Dibenzylaminverbindung und deren medizinische verwendung |
| BR0315041A (pt) | 2002-10-04 | 2005-08-16 | Millennium Pharm Inc | Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| AU2003283769A1 (en) | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| WO2004085401A1 (fr) * | 2003-03-28 | 2004-10-07 | Pfizer Products Inc. | Derives de 1,2,3,4-tetrahydro- et 1,2 dihydro-quinoleine et 1,2,3,4-tetrahydro-quinoxaline 1,2,4-substitues, utiles comme inhibiteurs de cetp pour le traitement de l'atherosclerose et de l'obesite |
| WO2005011635A2 (fr) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles |
| KR20060085675A (ko) | 2003-10-08 | 2006-07-27 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
| AU2005233160B2 (en) * | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| EA200700119A1 (ru) * | 2004-06-24 | 2007-10-26 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| US20070149567A1 (en) * | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
| WO2006033001A1 (fr) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Composes de quinoline |
| ZA200707498B (en) | 2005-02-24 | 2008-11-26 | Millennium Pharm Inc | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| WO2006098394A1 (fr) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| CL2008000684A1 (es) | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| EP2379547A1 (fr) | 2008-12-16 | 2011-10-26 | Schering Corporation | Dérivés de pyridopyrimidine et leurs procédés d'utilisation |
| TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| ES2825675T3 (es) | 2014-07-30 | 2021-05-17 | Hoffmann La Roche | Marcadores genéticos para predecir la reactividad al tratamiento con un agente que aumenta las HDL o que imita las HDL |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| WO1998033775A1 (fr) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | Derives de l'-1-acyl-1,2-dihydroquinoline substituee en 2 augmentant la concentration en cholesterol hdl |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Application Discontinuation
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/fr not_active Application Discontinuation
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 EP EP00971662A patent/EP1246804A1/fr not_active Withdrawn
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 CA CA002392979A patent/CA2392979A1/fr not_active Abandoned
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA26845A1 (fr) | 2004-12-20 |
| NO20022558D0 (no) | 2002-05-29 |
| TNSN00231A1 (fr) | 2002-05-30 |
| KR20020058057A (ko) | 2002-07-12 |
| BR0015836A (pt) | 2002-08-06 |
| GT200000199A (es) | 2002-05-23 |
| JP2003515592A (ja) | 2003-05-07 |
| PE20010904A1 (es) | 2001-09-10 |
| EA200200510A1 (ru) | 2002-10-31 |
| IS6338A (is) | 2002-04-12 |
| PA8506301A1 (es) | 2002-08-26 |
| AP2002002531A0 (en) | 2002-06-30 |
| EP1246804A1 (fr) | 2002-10-09 |
| CN1402711A (zh) | 2003-03-12 |
| ECSP003792A (es) | 2002-04-23 |
| CA2392979A1 (fr) | 2001-06-07 |
| WO2001040190A1 (fr) | 2001-06-07 |
| AU1048801A (en) | 2001-06-12 |
| TR200201446T2 (tr) | 2002-11-21 |
| CO5271716A1 (es) | 2003-04-30 |
| NO20022558L (no) | 2002-05-29 |
| PL355892A1 (en) | 2004-05-31 |
| OA12099A (en) | 2006-05-04 |
| MXPA02005354A (es) | 2002-12-11 |
| UY26454A1 (es) | 2001-07-31 |
| HUP0203521A2 (hu) | 2003-02-28 |
| BG106854A (bg) | 2002-12-29 |
| IL149097A0 (en) | 2002-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200200277A (et) | 4-karboksüamino-2-etüül-1,2,3,4-tetrahüdrokinoliini kristall kui CETP inhibiitor | |
| EE200100166A (et) | 4-karboksüamino-2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid | |
| EE200100167A (et) | 4-amino-asendatud 2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid | |
| EE200200140A (et) | Pteridinoonid kui kinaasi inhibiitorid | |
| NO20013003D0 (no) | Kinolin-derivater | |
| DK1073639T3 (da) | Chinolinderivater | |
| ATE250036T1 (de) | Chinolinderivate | |
| DK1114033T3 (da) | 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoliner som CETP-inhibitorer | |
| NO20016319D0 (no) | VLA-4 inhibitor-forbindelser | |
| NO20006039L (no) | Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin | |
| ATE229005T1 (de) | Chinolinderivate | |
| CY2009001I2 (el) | Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης | |
| EE200100039A (et) | Ftalasiinderivaadid kui fosfodiesteraas-4 inhibiitorid | |
| NO20023013L (no) | Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer | |
| DE60107074D1 (de) | Kristallin form ii von cabergolin | |
| ATE339438T1 (de) | Substanziell kristalline form von melagatran | |
| NO20022564D0 (no) | Nye androgener | |
| ATE243197T1 (de) | Kristallformen von osanetant | |
| IL143779A0 (en) | Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation | |
| EE200100381A (et) | Morfolinobensamiidi uued soolad | |
| NO20013407D0 (no) | Fremgangsmåte for fremstilling av kinolinkarbaldehyd | |
| DE50003014D1 (de) | N-substituierte perhydrodiazine | |
| DK1224179T3 (da) | Natrium-hydrogen-udbytter type 1-inhibitorkrystaller | |
| DE60038936D1 (de) | Einkristallziehvorrichtung | |
| DE60014760D1 (de) | Verwendung von Primaquinederivaten zum behandlung von Malaria |